Treatment with the combination of KRAS G12C inhibitor, PI3K inhibitor, and SHP2 inhibitor resulted in tumor regression in mouse models of acquired resistance to KRAS G12C inhibitor, AMG510 [79]. Here, KRAS is linked to neoplasm.